GlassScriptPhysician profile
Jessica Krop
NPI 1659043305
$1,163.86
in general payments reported to CMS, 2019-2025
13 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.30 · 2023: $119 · 2024: $596 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $452.12 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $165.77 | 2023-2025 | Airsupra |
| Lilly USA, LLC | $113.90 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $102.59 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $95.55 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.58 | 2024-2025 | Xifaxan |
| Amgen INC. | $36.08 | 2024-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $32.00 | 2025 | Penmenvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.77 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $27.42 | 2023 | |
| Eisai INC. | $19.91 | 2024 | |
| Photonicare INC | $18.34 | 2025 | Otosight Middle Ear Scope |
| Novartis Pharmaceuticals Corporation | $15.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Krop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.